Skip to main content
Erschienen in: Diabetologia 1/2011

01.01.2011 | Article

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

verfasst von: P. L. Drury, R. Ting, D. Zannino, C. Ehnholm, J. Flack, M. Whiting, R. Fassett, J.-C. Ansquer, P. Dixon, T. M. E. Davis, C. Pardy, P. Colman, A. Keech

Erschienen in: Diabetologia | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Methods

Baseline and year 2 renal status were examined in relation to clinical and biochemical characteristics. Outcomes included total cardiovascular disease (CVD), cardiac and non-cardiac death over 5 years.

Results

Lower estimated GFR (eGFR) vs eGFR ≥90 ml min−1 1.73 m−2 was a risk factor for total CVD events: (HR [95% CI] 1.14 [1.01–1.29] for eGFR 60–89 ml min−1 1.73 m−2; 1.59 [1.28–1.98] for eGFR 30–59 ml min−1 1.73 m−2; p < 0.001; adjusted for other characteristics). Albuminuria increased CVD risk, with microalbuminuria and macroalbuminuria increasing total CVD (HR 1.25 [1.01–1.54] and 1.19 [0.76–1.85], respectively; p = 0.001 for trend) when eGFR ≥90 ml min−1 1.73 m−2. CVD risk was further modified by renal status changes over the first 2 years. In multivariable analysis, 77% of the effect of eGFR and 81% of the effect of albumin:creatinine ratio were accounted for by other variables, principally low HDL-cholesterol and elevated blood pressure.

Conclusions/interpretation

Reduced eGFR and albuminuria are independent risk factors for cardiovascular events and mortality rates in a low-risk population of mainly European ancestry. While their independent contributions to CVD risk appear small when other risk factors are considered, they remain excellent surrogate markers in clinical practice because they capture risk related to a number of other characteristics. Therefore, both should be considered when assessing prognosis and treatment strategies in patients with diabetes, and both should be included in risk models.
Literatur
1.
Zurück zum Zitat Hostetter TH (2004) Chronic kidney disease predicts cardiovascular disease. N Engl J Med 351:1344–1346CrossRefPubMed Hostetter TH (2004) Chronic kidney disease predicts cardiovascular disease. N Engl J Med 351:1344–1346CrossRefPubMed
2.
Zurück zum Zitat Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147PubMed Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147PubMed
3.
Zurück zum Zitat Yokoyama H, Oishi M, Kawai K, Sone H (2008) Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes: JDDM study 16. Diabet Med 25:1426–1432CrossRefPubMed Yokoyama H, Oishi M, Kawai K, Sone H (2008) Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes: JDDM study 16. Diabet Med 25:1426–1432CrossRefPubMed
4.
Zurück zum Zitat So WY, Kong AP, Ma RC et al (2006) Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diab Care 29:2046–2052CrossRef So WY, Kong AP, Ma RC et al (2006) Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diab Care 29:2046–2052CrossRef
5.
Zurück zum Zitat Bruno G, Merlett F, Biggeri A et al (2005) Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427–434CrossRefPubMed Bruno G, Merlett F, Biggeri A et al (2005) Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427–434CrossRefPubMed
6.
Zurück zum Zitat Bruno G, Merletti F, Bargero G et al (2007) Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 50:941–948CrossRefPubMed Bruno G, Merletti F, Bargero G et al (2007) Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 50:941–948CrossRefPubMed
7.
Zurück zum Zitat Henry RM, Kostense PJ, Bos G et al (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407CrossRefPubMed Henry RM, Kostense PJ, Bos G et al (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407CrossRefPubMed
8.
Zurück zum Zitat Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V (2007) All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study. Diabet Med 24:10–17CrossRefPubMed Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V (2007) All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study. Diabet Med 24:10–17CrossRefPubMed
9.
Zurück zum Zitat Valmadrid CT, Klein R, Moss SE, Klein BEK (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100CrossRefPubMed Valmadrid CT, Klein R, Moss SE, Klein BEK (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100CrossRefPubMed
10.
Zurück zum Zitat Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482CrossRefPubMed Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482CrossRefPubMed
11.
Zurück zum Zitat Colhoun HM, Lee ET, Bennett PH et al (2001) Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S46–S53CrossRefPubMed Colhoun HM, Lee ET, Bennett PH et al (2001) Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S46–S53CrossRefPubMed
12.
Zurück zum Zitat Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH (2006) The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 185:140–144PubMed Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH (2006) The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 185:140–144PubMed
13.
Zurück zum Zitat MacIsaac RJ, Tsalamandris C, Thomas MC et al (2006) Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 49:1686–1689CrossRefPubMed MacIsaac RJ, Tsalamandris C, Thomas MC et al (2006) Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 49:1686–1689CrossRefPubMed
14.
Zurück zum Zitat The FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861CrossRef The FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861CrossRef
15.
Zurück zum Zitat The FIELD Study Investigators (2004) The need for a large scale of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 3:9CrossRef The FIELD Study Investigators (2004) The need for a large scale of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 3:9CrossRef
16.
Zurück zum Zitat Vassalotti JA, Stevens LA, Levey AS (2007) Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 50:169–180CrossRefPubMed Vassalotti JA, Stevens LA, Levey AS (2007) Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 50:169–180CrossRefPubMed
17.
Zurück zum Zitat LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin in 9,014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359:1379–1387CrossRef LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin in 9,014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359:1379–1387CrossRef
18.
Zurück zum Zitat Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
19.
Zurück zum Zitat Patel A (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed Patel A (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed
20.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed
21.
Zurück zum Zitat Heerspink HJL, Brinkman JW, Bakker SJL, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRef Heerspink HJL, Brinkman JW, Bakker SJL, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRef
22.
Zurück zum Zitat Harrell FE (2001) Regression modelling strategies. Springer, New York Harrell FE (2001) Regression modelling strategies. Springer, New York
23.
Zurück zum Zitat Kuk AYC (1984) All subsets in proportional hazards models. Biometrika 71:587–592CrossRef Kuk AYC (1984) All subsets in proportional hazards models. Biometrika 71:587–592CrossRef
24.
Zurück zum Zitat Vaziri ND, Navab M, Fogelman AM (2010) HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6:287–296CrossRefPubMed Vaziri ND, Navab M, Fogelman AM (2010) HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6:287–296CrossRefPubMed
25.
Zurück zum Zitat Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:F262–F272CrossRefPubMed Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:F262–F272CrossRefPubMed
26.
Zurück zum Zitat McCullough PA, Verrill TA (2010) Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 122:25–34CrossRefPubMed McCullough PA, Verrill TA (2010) Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 122:25–34CrossRefPubMed
27.
Zurück zum Zitat Arici M, Walls J (2001) End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407–414CrossRefPubMed Arici M, Walls J (2001) End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407–414CrossRefPubMed
28.
Zurück zum Zitat Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524–1538CrossRefPubMed Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524–1538CrossRefPubMed
29.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169CrossRefPubMed
30.
Zurück zum Zitat Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555–562PubMed Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555–562PubMed
31.
Zurück zum Zitat Wright RS, Reeder GS, Herzog CA et al (2002) Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137:563–570PubMed Wright RS, Reeder GS, Herzog CA et al (2002) Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137:563–570PubMed
32.
Zurück zum Zitat Peter AM, Keisha RS, Steven B, Michael PH, Mukesh G, Harold JM (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226–232CrossRef Peter AM, Keisha RS, Steven B, Michael PH, Mukesh G, Harold JM (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226–232CrossRef
33.
Zurück zum Zitat Stehouwer CA, Zeldenrust GC, den Ottolander GH, Hackeng WHL, Donker AJM, Nauta JJP (1992) Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319–323CrossRefPubMed Stehouwer CA, Zeldenrust GC, den Ottolander GH, Hackeng WHL, Donker AJM, Nauta JJP (1992) Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319–323CrossRefPubMed
34.
Zurück zum Zitat Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34:55–68CrossRefPubMed Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34:55–68CrossRefPubMed
35.
Zurück zum Zitat Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 58:1703–1710CrossRefPubMed Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 58:1703–1710CrossRefPubMed
36.
Zurück zum Zitat Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
37.
Zurück zum Zitat Uhlig K, Levey AS, Sarnak MJ (2003) Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 16:118–127CrossRefPubMed Uhlig K, Levey AS, Sarnak MJ (2003) Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 16:118–127CrossRefPubMed
38.
Zurück zum Zitat Ninomiya T, Perkovic V, de Galan B et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813–1821CrossRefPubMed Ninomiya T, Perkovic V, de Galan B et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813–1821CrossRefPubMed
39.
Zurück zum Zitat Hemmelgarn BR, Manns BJ, Lloyd A et al (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303:423–429CrossRefPubMed Hemmelgarn BR, Manns BJ, Lloyd A et al (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303:423–429CrossRefPubMed
40.
Zurück zum Zitat Yang X, So WY, Tong PCY et al (2008) Development and validation of an all-cause mortality risk score in type 2 diabetes: the Hong Kong Diabetes Registry. Arch Intern Med 168:451–457CrossRefPubMed Yang X, So WY, Tong PCY et al (2008) Development and validation of an all-cause mortality risk score in type 2 diabetes: the Hong Kong Diabetes Registry. Arch Intern Med 168:451–457CrossRefPubMed
41.
Zurück zum Zitat Yang X, So W-Y, Kong APS et al (2008) Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101:596–601CrossRefPubMed Yang X, So W-Y, Kong APS et al (2008) Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101:596–601CrossRefPubMed
42.
Zurück zum Zitat Foster MC, Hwang S, Larson MG et al (2007) Cross-classification of microalbuminuria and reduced glomerular filtration rate. Arch Intern Med 167:1386–1392CrossRefPubMed Foster MC, Hwang S, Larson MG et al (2007) Cross-classification of microalbuminuria and reduced glomerular filtration rate. Arch Intern Med 167:1386–1392CrossRefPubMed
43.
Zurück zum Zitat Young BA, Maynard C, Boyko EJ (2003) Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diab Care 26:2392–2399CrossRef Young BA, Maynard C, Boyko EJ (2003) Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diab Care 26:2392–2399CrossRef
44.
Zurück zum Zitat Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182–187CrossRefPubMed Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182–187CrossRefPubMed
45.
Zurück zum Zitat Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group (2006) Risk factors for renal dysfunction in type 2 diabetes. UKPDS 74. Diabetes 55:1832–1839CrossRefPubMed Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group (2006) Risk factors for renal dysfunction in type 2 diabetes. UKPDS 74. Diabetes 55:1832–1839CrossRefPubMed
46.
Zurück zum Zitat Charlton JMSC, Latinovic RBSC, Gulliford MCF (2008) Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care 31:1761–1766CrossRefPubMed Charlton JMSC, Latinovic RBSC, Gulliford MCF (2008) Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care 31:1761–1766CrossRefPubMed
47.
Zurück zum Zitat Gu K, Cowie CC, Harris MI (1998) Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21:1138–1145CrossRefPubMed Gu K, Cowie CC, Harris MI (1998) Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21:1138–1145CrossRefPubMed
48.
Zurück zum Zitat Goff DC Jr, Gerstein HC, Ginsberg HN et al (2007) Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99:S4–S20 Goff DC Jr, Gerstein HC, Ginsberg HN et al (2007) Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99:S4–S20
49.
Zurück zum Zitat The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
Metadaten
Titel
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
verfasst von
P. L. Drury
R. Ting
D. Zannino
C. Ehnholm
J. Flack
M. Whiting
R. Fassett
J.-C. Ansquer
P. Dixon
T. M. E. Davis
C. Pardy
P. Colman
A. Keech
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 1/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1854-1

Weitere Artikel der Ausgabe 1/2011

Diabetologia 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.